tetano
Editor, Senior Moderator
NPJ Vaccines
. 2024 Nov 11;9(1):215.
doi: 10.1038/s41541-024-01016-6. Neutralization of SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 by human and murine sera
Kun Xu[SUP] #[/SUP][SUP] 1 [/SUP], Yaling An[SUP] #[/SUP][SUP] 2 [/SUP], Xueyuan Liu[SUP] #[/SUP][SUP] 3 [/SUP], Haitang Xie[SUP] #[/SUP][SUP] 4 [/SUP], Dedong Li[SUP] 2 [/SUP], Ting Yang[SUP] 3 [/SUP], Minrun Duan[SUP] 2 [/SUP], Yuanzhuo Wang[SUP] 1 [/SUP], Xin Zhao[SUP] 2 [/SUP], Lianpai Dai[SUP] 2 [/SUP], George F Gao[SUP] 5 6 [/SUP]
Affiliations
We report SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 neutralizing antibody titers. They displayed increased immune evasion compared to JN.1, especially KP.1 and KP.3, for participants who experienced BF.7/BA.5.2 breakthrough infection or received bivalent (delta/BA.5) vaccine boosting. Second XBB sub-variants breakthrough infection enhanced the neutralization responses. HK.3-JN.1 RBD-heterodimer induced balanced and potent neutralizing responses against recently-circulating SARS-CoV-2 sub-variants in mice, supporting to replace the COVID-19 antigen containing JN.1 or its sub-variants.
. 2024 Nov 11;9(1):215.
doi: 10.1038/s41541-024-01016-6. Neutralization of SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 by human and murine sera
Kun Xu[SUP] #[/SUP][SUP] 1 [/SUP], Yaling An[SUP] #[/SUP][SUP] 2 [/SUP], Xueyuan Liu[SUP] #[/SUP][SUP] 3 [/SUP], Haitang Xie[SUP] #[/SUP][SUP] 4 [/SUP], Dedong Li[SUP] 2 [/SUP], Ting Yang[SUP] 3 [/SUP], Minrun Duan[SUP] 2 [/SUP], Yuanzhuo Wang[SUP] 1 [/SUP], Xin Zhao[SUP] 2 [/SUP], Lianpai Dai[SUP] 2 [/SUP], George F Gao[SUP] 5 6 [/SUP]
Affiliations
- PMID: 39528468
- PMCID: PMC11555263
- DOI: 10.1038/s41541-024-01016-6
We report SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 neutralizing antibody titers. They displayed increased immune evasion compared to JN.1, especially KP.1 and KP.3, for participants who experienced BF.7/BA.5.2 breakthrough infection or received bivalent (delta/BA.5) vaccine boosting. Second XBB sub-variants breakthrough infection enhanced the neutralization responses. HK.3-JN.1 RBD-heterodimer induced balanced and potent neutralizing responses against recently-circulating SARS-CoV-2 sub-variants in mice, supporting to replace the COVID-19 antigen containing JN.1 or its sub-variants.